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Aim
Drug resistance mutations are routinely detected using
standard Sanger sequencing, which does not detect
minor variants with a frequency below 20%. The impact
of detecting minor variants generated by ultra-deep
sequencing (UDS) on HIV drug-resistance (DR) inter-
pretations has not yet been studied.
Methods
Fifty HIV-1 patients who experienced virological failure
were included in this retrospective study. The HIV-1
UDS protocol was performed using the GS Junior (Roche
454 Life Sciences Branford, CT). This UDS protocol
allowed the detection and quantification of minor and
major HIV-1 protease and reverse transcriptase variants
related to genotypes A, B, C, E, F and G. DeepChek®-
HIV (ABL, SA and TherapyEdgeTM, USA) simplified
drug resistance (DR) interpretation software was used to
compare Sanger sequencing and UDS at two different
thresholds (≥1% and ≥20%). DeepChek®-HIV utilizes the
ANRS, HIVdb and Rega algorithms.
Results
The total time required for the UDS protocol was found
to be approximately three times longer than Sanger
sequencing with equivalent reagent costs. UDS detected
all of the mutations found by population sequencing
and identified additional resistance variants in all
patients, primarily by using 1% sensitivity. An analysis of
DR revealed a total of 643 and 224 clinically relevant
mutations by UDS and Sanger sequencing, respectively.
Three resistance mutations with >20% prevalence were
detected solely by UDS: A98S (23%), E138A (21%) and
V179I (25%). A significant difference in the DR interpre-
tations for 19 antiretroviral drugs was observed between
the UDS and Sanger sequencing methods. Y181C and
T215Y were the most frequent mutations associated
with interpretation differences. The major discrepancies
between Sanger and UDS were primarily found at the
1% threshold in the three algorithms.
Conclusion
UDS was more sensitive than the standard Sanger sequen-
cing. A combination of UDS and DeepChek® software for
the interpretation of DR results saved a considerable
amount of time and would help clinicians provide suitable
treatments. A cut-off of 1% allowed a better characteriza-
tion of the viral population by identifying additional resis-
tance mutations and improving the DR interpretation.
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